Valuation: Pfizer Inc

Market Cap 14TCr 12TCr 11TCr 10TCr 20TCr 13,46900Cr 20TCr 1,35700Cr 53TCr 6,62200Cr 53TCr 51TCr 22,89500Cr P/E 2026 *
12.5x
P/E 2027 * 12.9x
Enterprise Value 19TCr 17TCr 15TCr 14TCr 27TCr 18,22300Cr 27TCr 1,83500Cr 72TCr 8,95900Cr 71TCr 70TCr 30,97600Cr EV / Sales 2026 *
3.06x
EV / Sales 2027 * 3.08x
Free-Float
59.06%
Yield 2026 *
7.02%
Yield 2027 * 7.08%

Last Transcript: Pfizer Inc

Manager TitleAgeSince
Chief Executive Officer 64 01/01/2019
Director of Finance/CFO 60 02/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2007
Director TitleAgeSince
Director/Board Member 68 01/09/2007
Director/Board Member 62 27/09/2013
Chairman 64 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%+1.43%+47.17%+161.40% 1,06700Cr
+1.59%+4.09%+56.51%+52.79% 63TCr
+0.95%+1.91%+36.30%+83.13% 46TCr
+1.60%+6.25%+37.00%+30.00% 35TCr
-0.60%+1.52%+36.67%+39.80% 30TCr
-0.14%+0.60%+17.29%+18.19% 26TCr
+0.09%-2.82%-29.09%-41.29% 22TCr
+1.22%+2.66%+22.66%+59.81% 20TCr
-1.18%-3.70%+11.28%+67.43% 16TCr
Average +0.49%+1.33%+26.20%+52.36% 40.48TCr
Weighted average by Cap. +0.76%+1.95%+35.99%+78.15%

Financials

2026 *2027 *
Net sales 6.17TCr 5.42TCr 5.04TCr 4.63TCr 8.7TCr 5,94600Cr 8.83TCr 60TCr 23TCr 2,92300Cr 23TCr 23TCr 10,10800Cr 5.94TCr 5.21TCr 4.85TCr 4.45TCr 8.36TCr 5,71800Cr 8.49TCr 58TCr 22TCr 2,81100Cr 22TCr 22TCr 9,71900Cr
Net income 1.06TCr 933.38Cr 868.02Cr 796.52Cr 1.5TCr 1,02300Cr 1.52TCr 10TCr 4.03TCr 50TCr 3.99TCr 3.9TCr 1,74000Cr 1.03TCr 901.82Cr 838.68Cr 769.6Cr 1.45TCr 99TCr 1.47TCr 9.96TCr 3.89TCr 49TCr 3.85TCr 3.77TCr 1,68100Cr
Net Debt 4.94TCr 4.34TCr 4.03TCr 3.7TCr 6.95TCr 4,75400Cr 7.06TCr 48TCr 19TCr 2,33700Cr 19TCr 18TCr 8,08100Cr 4.32TCr 3.79TCr 3.53TCr 3.24TCr 6.08TCr 4,15700Cr 6.17TCr 42TCr 16TCr 2,04400Cr 16TCr 16TCr 7,06600Cr
Logo Pfizer Inc
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (42.9%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (28%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (26.9%); - other (2.2%). The United States accounts for 59.2% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-